ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on X

Kidney Week

Please note that you are viewing an archived section from 2022 and some content may be unavailable. To unlock all content for 2022, please visit the archives.

Abstract: FR-PO456

Inhibition of H3K4 Trimethylation Ameliorates Peritoneal Fibrosis and Senescence

Session Information

Category: Dialysis

  • 702 Dialysis: Home Dialysis and Peritoneal Dialysis


  • Hara, Daisuke, Hiroshima University Hospital, Hiroshima, Japan
  • Sasaki, Kensuke, Hiroshima University Hospital, Hiroshima, Japan
  • Nakashima, Ayumu, Hiroshima University Hospital, Hiroshima, Japan
  • Masaki, Takao, Hiroshima University Hospital, Hiroshima, Japan

Senescence is induced by aging as well as various stimuli, resulting in the development of organ inflammation and fibrosis. Recently, the accumulation of p16INK4a-positive cells is considered as a feature of organ senescence, and p16INK4a gene expression is regulated by Mixed-lineage leukemia 1 (MLL1)/WD-40 repeat protein 5 (WDR5)-mediated histone 3 lysine 4 trimethylation (H3K4me3). In this study, we investigated whether MLL1/WDR5 complex inhibition ameliorates peritoneal senescence together with peritoneal inflammation and fibrosis in methylglyoxal (MGO) induced peritoneal injury mice and cultured human peritoneal mesothelial cells (HPMCs).


Peritoneal fibrosis was induced by intraperitoneal injection of MGO in male C57/B6 mice for 3 weeks. MM-102, a MLL1/WDR5 complex inhibitor, was administered subcutaneously at the same time. After 3 weeks of treatment, peritoneal tissues were examined. In an in vitro study, TGF-β1 stimulated HPMCs were examined with or wihout MM-102 preincubation.Chromatin immunoprecipitation (ChIP) assays were performed to clarify the status of p16INK4a gene promoter as an H3K4me3-enrichment region. Human nonadherent cells were isolated from the effluent of PD patients.


MLL1 was upregulated in the peritoneum of MGO-injected mice, TGF-β1- stimulated HPMCs and human nonadherent cells. MM-102 significantly suppressed p16INK4a expression, as well as submesothelial zone thickness and cell density in MGO-injected mice. Immunohistochemical staining revealed that MM-102 decreased not only H3K4me3 and p16INK4a expression, but also peritoneal inflammation and collagen deposition. Moreover, p16INK4a expression was positively correlated with dialysate-to-plasma (D/P) ratio of creatinine in PD patients. In the in vitro study, MM-102 suppressed TGF-β1-induced upregulation of p16INK4a, H3K4me3 and fibrotic markers in HPMCs. Finally, ChIP assay revealed that MM-102 decreased the H3K4me3 levels at the promoter of p16INK4a.


The MLL1/WDR5 inhibitor MM-102 ameliorates peritoneal inflammation and fibrosis through suppression of senescence.